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Hemophilia A is an X-linked rescessive bleeding disorder that results from F8 gene aberrations.
Previously, we established embryonic stem (ES) cells (tet-226aa/N6-Ainv18) that secrete
human factor VIII (hFVIII) by introducing the human F8 gene in mouse Ainv18 ES cells. Here,
we explored the potential of cell transplantation therapy for hemophilia A using the ES cells.
Transplant tet-226aa/N6-Ainv18 ES cells were injected into the spleens of severe combined
immunodeficiency (SCID) mice, carbon tetrachloride (CCl4)-pretreated wild-type mice, and
CCl4-pretreated hemophilia A mice. F8 expression was induced by doxycycline in drinking
water, and hFVIII-antigen production was assessed in all cell transplantation experiments.
Injecting the ES cells into SCID mice resulted in an enhanced expression of the hFVIII antigen;
however, teratoma generation was confirmed in the spleen. Transplantation of ES cells into
wild-type mice after CCl4-induced liver injury facilitated survival and engraftment of trans-
planted cells without teratoma formation, resulting in hFVIII production in the plasma.
Although CCl4 was lethal to most hemophilia A mice, therapeutic levels of FVIII activity, as well
as the hFVIII antigen, were detected in surviving hemophilia A mice after cell transplantation.
Immunolocalization results for hFVIII suggested that transplanted ES cells might be engrafted atbody; ES,
t protein;
olymerase
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Embryonic stem cell treatment of hemophilia A 65the periportal area in the liver. Although the development of a safer induction method for liver
regeneration is required, our results suggested the potential for developing an effective ES-cell
transplantation therapeutic model for treating hemophilia A in the future.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Hemophilia A is an inherited X-linked, recessive hemorrhagic
disorder caused by a deficiency of clotting factor VIII (FVIII)
and is commonly treated by FVIII replacement. Concentrated
FVIII products are derived from human plasma or produced
recombinantly. Advances in viral-screening and -inactivation
methods have improved the safety of plasma-derived
products. Furthermore, the infectious risk of recombinant FVIII
products is lowered by excluding human- or animal-derived
proteins from cell culture solutions [1]. However, FVIII concen-
trates remain extraordinarily expensive, and frequent
injections are required for FVIII replenishment, especially with
severe hemophilia A patients.
Since hemophilia A is a single-gene disorder and small
increases in FVIII levels exert a curative influence, the dis-
ease is a good candidate for gene therapy. However, prob-
lems are associated with gene therapy, such as the
development of leukemia and decreased target-protein
expression following cytotoxic CD8 T-cell induction against
viral vector-derived capsid epitopes [2]. Nevertheless, a sin-
gle injection of an adeno-associated virus serotype 8 vector
in patients with severe hemophilia B caused prolonged factor
IX (FIX) overexpression and clinical improvement [3]. How-
ever, viral vectors employed in gene therapy cannot deliver
the F8 gene due to its large size. Therefore, truncated F8
gene variants, such as a B-domain-deleted variant, have
been used, but successful hemophilia A gene therapy using
viral vectors has not been achieved clinically. A recent study
using a hemophilia A mouse model demonstrated that trans-
ducing the entire F8 gene via the piggyBac vector improved
clotting activity [4]. However, as the vector preferentially
integrates near transcriptional start sites [5], insertional
mutagenesis and genotoxicity remain significant concerns.
As the liver is the major site of FVIII synthesis, liver
transplantation is effective in hemophilia A patients [6];
however, the lack of donor organs hinders clinical applica-
tions. Recent studies revealed that the main source of FVIII
is liver sinusoidal endothelial cells (LSECs), and transplanta-
tion experiments using murine or human LSECs in hemophi-
lia A mice demonstrated symptomatic improvement [7].
However, such transplantation requires a donor liver from
which LSECs can be isolated, and contamination with
different donor cells remains a potential problem. Several
therapies have been investigated using cells capable of
differentiating into LSECs [8–11].
Considering their potential for multilineage development
and illimitable proliferation potential, embryonic stem (ES)
cells may enable cell transplantation therapy. Fair et al.
[12] reported that injecting mouse ES cells into the livers
of hemophilia B mice corrected FIX deficiency. However,
there have been few reports describing cell therapy for
hemophilia A using ES cells. Previously, we establishedmouse Ainv18 ES cells (tet-226aa/N6-Ainv18), which secrete
human FVIII (hFVIII) by introducing the human F8 gene [13].
Here, we investigated ES-cell transplantation therapy
against hemophilia A.
Materials and methods
Mice
All animal experiments were performed in accordance with
the ARRIVE (Animal Research: Reporting of In Vivo Experi-
ments) guidelines and national regulations after approval
from the institutional animal-care committee. Severe com-
bined immunodeficiency (SCID) mice and wild-type (WT)
C57/BL6 mice were purchased from CLEA Japan (Tokyo,
Japan). F8-deficient (hemophilia A) mice were provided by
Professor Yoichi Sakata (Jichi Medical University, Shimot-
suke, Japan) and back-crossed for over eight generations
with the C57/BL6 background as previously described [14].
Mouse blood was collected by retro-orbital bleeding at the
indicated times and placed into 3.8% sodium citrate buffer.
Immediately after blood sampling, plasma was isolated by
centrifugation to evaluate FVIII activity (FVIII:C) and human
FVIII-antigen (hFVIII:Ag).
FVIII assay
Mouse plasma samples were diluted with Owren’s Veronal
Buffer (Sysmex, Kobe, Japan). FVIII:C was measured in a
one-stage aPTT clotting assay in a KC10A coagulometer
(Amelung, Lemgo, Germany) using human FVIII-deficient
plasma (George King Biomedical, Overland Park, KS, USA).
Activated partial thromboplastin and CaCl2 were purchased
from bioMerieux (Durham, NC, USA). hFVIII:Ag was quanti-
fied using the VisuLize FVIII Antigen ELISA Kit (Affinity
Biologicals, Ancaster, ON, Canada). For measurements of
both FVIII:C and hFVIII:Ag, a standard curve was generated
using normal human plasma (Sysmex). The detection limits
of the FVIII:C and FVIII:Ag assays were 0.1% and 2 ng/mL,
respectively.
ES cells
Production of tet-226aa/N6 ES cells was described
previously [13]. Briefly, for efficient production of the
active FVIII protein, we employed 226aa/N6-F8 cDNA [15].
The 226aa/N6-F8 construct encodes a shortened B-domain
of 226 amino acids with six N-linked oligosaccharides. Green
fluorescent protein (GFP)–brachyury (Bry) Ainv18 ES cells,
established by targeting the GFP cDNA to the Bry locus in
Ainv18 ES cells [16], were transfected with the 226aa/
N6-plox targeting plasmids, yielding tet-226aa/N6 ES cells.
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Figure 1 Transplanting ES cells into WT/hemophilia A mice
with CCl4-hepatic injury. Intraperitoneal injection of CCl4
(0.5 mL/kg) was performed twice weekly in WT mice (n = 6)
and hemophilia A mice (n = 10). One day after the second
intraperitoneal CCl4 injection, 1  105 ES cells were trans-
planted into the spleens. hFVIII:Ag levels were assessed every
10 days through post-transplantation Day 30 in WT mice, or
post-transplantation Day 10 in hemophilia A mice. ES = embry-
onic stem; hFVIII:Ag = human factor VIII antigen.
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tetracycline (tet)-inducible promoter following doxycycline
(Dox) exposure. Undifferentiated tet-226aa/N6 ES cells dif-
ferentiated into mesendodermal embryoid bodies (EBs)
[13,16]. Day-3.5 EBs were dissociated with trypsin–EDTA,
stained with anti-mouse c-kit-phycoerythrin (BD PharMin-
gen, San Diego, CA, USA), and sorted in a FACSAria cell sor-
ter (Becton Dickinson, San Jose, CA, USA). We prepared
GFP-Bry+/c-kit+ cells for transplantation, because they con-
tained a definitive endoderm population and produced
active hFVIII more efficiently than pre-sorted populations
[13]. The GFP-Bry+/c-kit+ population was subsequently used
for all transplantations.
Cell transplantation into SCID mice
SCID mice were used, because they did not demonstrate
rejection responses. Transplant cells (1  106 cells) were
injected into the spleens of three SCID mice anesthetized
with isoflurane. One control mouse was injected with cul-
ture media alone. At 1-week post-transplantation, F8
expression was induced by replacing the normal drinking
water with Dox-containing water (2 mg/mL). Subsequently,
blood samples were collected weekly, and hFVIII:Ag was
assessed. At 3-weeks post-transplantation, two of the three
mice were sacrificed, and the livers and spleens were har-
vested, while the remaining mouse underwent a splenec-
tomy. The resected livers and spleens were fixed with 10%
formalin for hematoxylin and eosin (H&E) staining. Total
RNA was extracted from the livers and spleens and reverse
transcribed into cDNA [17]. F8 gene expression in each
organ was evaluated by polymerase chain reaction (PCR)
using human F8-specific primers [13]. b-actin was used as
an endogenous control.
Cell transplantation into WT mice
For cell transplantations into WT mice, liver injury was
induced by carbon tetrachloride (CCl4) administration with
the expectation of better engraftment of transplanted
cells. CCl4 diluted in corn oil [10% (v/v), 0.5 mL/kg] was
injected intraperitoneally on Day-4 and Day-1. On Day 0,
1  105 cells (one-tenth of the cell number used with SCID
mice) were injected into the spleen. After transplantation,
intraperitoneal CCl4 injection was continued twice/week
until Day 30. Dox-containing water was given to mice at 1-
week post-transplantation. Blood samples were collected
on Day 0, Day 10, Day 20, and Day 30, after which the
obtained plasma were frozen at 80C until hFVIII:Ag was
evaluated (Fig. 1, upper panel).
Cell transplantation into hemophilia A mice
Liver injury was induced in hemophilia A mice using a
method similar to that described for WT-mice. For perioper-
ative hemostatic management, all hemophilia A mice were
intraperitoneally administered with 500 lL normal mouse
plasma 30 min before cell transplantation [18]. Mice were
sacrificed on Day 10, and plasma FVIII:C and hFVIII:Ag levels
were evaluated (Fig. 1, lower panel). Liver samples were
harvested on Day 10 and embedded in Tissue-Tek OCTcompound (Sakura Finetek, Tokyo, Japan) with liquid nitro-
gen. Liver tissue sections were incubated with a human-
specific polyclonal anti-FVIII antibody (Affinity Biologicals)
and then with an Alexa Fluor 488-conjugated anti-sheep
immunoglobulin G (Molecular Probes, Eugene, OR, USA).
Cell nuclei were counterstained using the ProLong-Gold
Antifade reagent with 40,6-diamidino-2-phenylindole (DAPI;
Invitrogen, Carlsbad, CA). Negative controls were prepared
using untreated mouse livers from hemophilia A mice. Fluo-
rescent detection of the hFVIII protein and cell nuclei was
performed using a FluoView FV1000 confocal microscope
(Olympus, Tokyo, Japan).
Effect of CCl4 administration on plasma
coagulation-factor levels
To address how CCl4-induced liver injury affected
coagulation-factor production, a single dose of CCl4 was
intraperitoneally injected into WT mice. We injected CCl4
at a dose of 2 mL/kg (4-fold higher than the dose used in
transplantation experiments) to observe coagulation-factor
differences after inducing greater liver injury. Before injec-
tion and at 24-h post-injection, we measured the plasma
levels of coagulation factors, including fibrinogen and von
Willebrand factor (VWF) antigen, and the activities of pro-
thrombin and factors V, VII, VIII, IX, X, XI, and XII [17,19].
Results
FVIII expression in SCID mice
Before Dox administration beginning at 1-week post-
transplantation, hFVIII:Ag was undetectable in the plasma
of treated mice. hFVIII:Ag was also undetectable in untrans-
planted mice, even after Dox administration. At 1-week
post-Dox administration (2-weeks post-transplantation),
we detected elevated levels of hFVIII:Ag in all three mice.
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transplantation), hFVIII:Ag levels increased to 13–43% of
normal human plasma levels (Fig. 2Ai). However, masses
had formed in the abdomens of all mice. Laparotomies
revealed spleen tumors, which were histologically confirmed
as teratomas, consisting of muscle cells, chondrocytes,
glial-like cells, and hair-root cells (Fig. 2Aii). In one mouse
that underwent a splenectomy, hFVIII:Ag became unde-
tectable within 3-weeks post-surgery (6-weeks post-
transplantation). Reverse transcription-PCR analysis showed
detectable human F8 mRNA only in spleens with teratomas,
but not in the livers (Fig. 2Aiii), indicating that plasma hFVIII:
Ag was derived primarily from spleens with teratomas.
FVIII expression in WT mice
hFVIII:Ag was undetectable in WT mice before Dox adminis-
tration. Dox administration began at 1-week post-
transplantation, and hFVIII:Ag was detected in the plasma
from three of the six transplanted mice (0.4–1.5% hFVIII:
Ag of the normal hFVIII:Ag level) on Day 10. Although
hFVIII:Ag became undetectable in one mouse, two mice
continued to produce FVIII on Day 20. One mouse died on
Day 20 after blood collection, but the other mouse producedFigure 2 (A) ES-cell transplantation into SCID mice. (i) Plasma
production was suggested as the hFVIII:Ag level became undetectabl
mouse after ES-cell transplantation. H&E staining of splenic tumor s
muscle (mesoderm), (b) chondrocytes (mesoderm), (c) glial-like ce
100 lm. (iii) Expression of human F8 mRNA after ES-cell transplan
mouse spleen following ES-cell transplantation. L: liver; S, spleen.
circles, triangles, and squares indicate ES cell-transplanted WT mic
other three ES cell-transplanted WT mice. Open circles indicate res
of a hemophilia A mouse by confocal microscopy. Liver sections wer
DAPI (blue). Representative images of FVIII staining (bar, 100 lm) in
and 10 days post-ES-cell transplantation (ii) are shown. DAPI = 40,6
VIII; H&E = hematoxylin and eosin; hFVIII:Ag = human factor VIII antFVIII until Day 30 (Fig. 2B). CCl4-induced liver injury did not
cause fatal liver failure in WT mice. Tumor formation was
not observed by laparotomy in transplanted mouse spleens
or the livers.
Hemophilia A mice
Contrary to the WT mice, CCl4-induced liver injury was
lethal to F8-KO mice: six of the ten transplanted mice died
within 7-days post-transplantation. Four surviving mice
were subjected to blood collection on Day 10, and FVIII:C
and hFVIII:Ag were detected in each surviving mouse
(Table 1). One mouse (#780) demonstrated markedly higher
levels of FVIII:C and hFVIII:Ag (both >10%). Teratoma forma-
tion was not found in the spleens or livers of hemophilia A
mice. Liver samples were collected on Day 10 from trans-
planted mice, and hFVIII antigen was detected in the peri-
portal area by immunofluorescence staining using an
hFVIII-specific antibody (Fig. 2C).
Effect of CCl4 on plasma coagulation-factor levels
In WT mice, the plasma levels of most coagulation factors
significantly decreased 24 h post-CCl4 injection, includinghFVIII:Ag levels after ES-cell transplantation. Splenic hFVIII
e after a splenectomy. (ii) Splenic teratoma formation in a SCID
ections showed differentiation into various tissues, including (a)
lls (ectoderm), and (d) hair-root cells (ectoderm). Scale bars:
tation. Expression of human F8 mRNA was confirmed only in a
(B) Plasma hFVIII:Ag levels after ES-cell transplantation. Closed
e with detectable hFVIII:Ag. hFVIII:Ag was undetectable in the
ults from control mice. (C) FVIII immunolocalization in the liver
e stained for FVIII (green), and nuclei were counterstained with
the liver of hemophilia A mice without ES-cell transplantation (i)
-diamidino-2-phenylindole; ES = embryonic stem; FVIII = factor
igen; SCID = severe combined immunodeficiency.
68 S. Kasuda et al.fibrinogen, prothrombin, and factors V, VII, IX, and X. How-
ever, the plasma levels of FVIII:C and VWF antigen signifi-
cantly increased following injection (Fig. 3). Injection of
the same CCl4 dose into hemophilia A mice caused death
within 24 h in five of 16 hemophilia A mice, whereas no
hemophilia A mice died after administration with the same
volume of vehicle control (n = 6). WT mice (n = 16) showed
no mortality under the same conditions.
Discussion
Here, we investigated whether tet-226aa/N6-Ainv18 ES cells
integrate and produce hFVIII at the transplant site. Cell
infusion into the spleens of SCID mice caused increased
hFVIII:Ag levels, ranging from 10% to 40% of the normal
hFVIII:Ag level. However, teratomas developed in the
spleens, even though the transplanted cells differentiated
into liver EBs. Neoplastic transformation would facilitate
the production of enormous amounts of hFVIII.
Nevertheless, successful synthesis of hFVIII was encourag-
ing, although few mice were used. Next, cell-transferTable 1 FVIII activity and antigen levels 10 days after cell trans
Mouse No. FVIII:C
727 0.96
738 1.34
777 1.07
780 10.9
Note. FVIII:Ag = factor VIII antigen; FVIII:C = human factor VIII activity
Figure 3 Plasma levels of coagulation factors before (open bars) a
injected intraperitoneally with CCl4 (2 mL/kg), and plasma sampl
levels of prothrombin and factors V, VII, VIII, IX, X, XI, and XII were
measured by the Clauss method, and VWF antigen levels were m
statistical significance is shown as *p < 0.05, **p < 0.01, and ***p < 0
Willebrand factor.experiments were conducted using hemophilia A-model
mice. While transplanted cells might show low survival
due to the hemophilia A mice having normal immunocompe-
tence, it was expected that some of the engrafted cells
would potentially produce hFVIII with low teratoma inci-
dence. However, hFVIII was undetectable in hemophilia A
mice using the same cell transplantation procedure as that
used for SCID mice (not shown). Therefore, anticipating
increased survival rates of transplanted cells in the pres-
ence of liver-regeneration stimuli, cell transplantation was
performed in WT mice after intraperitoneal CCl4 administra-
tion. hFVIII was detected without teratoma formation in
some, but not all mice administered a reduced number of
transplant cells. Although intraperitoneal CCl4 administra-
tion was lethal to most hemophilia A mice, hFVIII:Ag was
detected in circulating blood and the periportal area of
the liver of surviving hemophilia A mice, suggesting that
tet-226aa/N6-Ainv18 ES cells are potentially useful for
treating hemophilia A mice.
To establish ES cells, early embryos (blastocyst stage)
are required as a source. Because ethical issues are associ-
ated with using human ES cells experimentally, practicalplantation in hemophilia A mice.
(%) FVIII:Ag (%)
2.74
4.84
2.99
10.9
.
nd after CCl4 administration (closed bars). WT mice (n = 4) were
es were obtained before and 24-hours post-injection. Activity
measured in a one-stage clotting assay, fibrinogen levels were
easured by ELISA. Data were analyzed by Student t test, and
.001. ELISA = enzyme-linked immunosorbent assay; VWF = von
Embryonic stem cell treatment of hemophilia A 69applications with human ES cells are limited. Ethical issues
regarding the source of ES cells and rejection responses
are resolved by the establishment of patient-derived
induced pluripotent stem (iPS) cells. Xu et al. [20] reported
successful iPS-cell therapy using a hemophilia A mouse
model. These authors differentiated iPS cells into endothe-
lial cells through EBs in the presence of a vascular endothe-
lial growth factor. Injection of iPS cell-derived endothelial
cells into the livers of X-ray-irradiated hemophilia A mice
resulted in successful engraftment into the sinusoids and
increased FVIII:C. However, this strategy cannot be directly
applied for treating human hemophilia A, because immuno-
logically mismatched iPS cells from other donors will be
rejected, and iPS cells from hemophilia A patients are
unsuitable for cell therapy due to F8 gene aberrations. For
human applications, regardless of the type of stem cells
used, introduction of the F8 gene into stem cells is, there-
fore, essential, unless an iPS cell bank possessing sufficient
iPS-cell variations to match all patients immunologically is
established.
The genetic risks of cell therapy have been reduced by
genome-editing technology, including transcription
activator-like effector nucleases and the CRISPR/Cas system
[21,22], which facilitates in situ correction of mutant
genes, reduced risks for random genome insertions, and
ex vivo selection of genetically safe cells. The survival rate
of transplanted cells remains unsatisfactory; therefore,
methods were developed to promote hepatic regeneration,
such as CCl4 treatment, X-ray irradiation, and partial hepa-
tectomy. As shown following CCl4-induced liver damage,
coagulation-factor activities decreased, except for FVIII
and VWF, which likely increased due to excessive release
from storage granules in damaged endothelial cells.
Because hemophilia A mice are intrinsically deficient in
FVIII, CCl4 treatment resulted in reduced activities in most
key coagulation factors, resulting in a tendency for severe
or sometimes lethal bleeding. Instead of using these inva-
sive methods clinically, novel methods for the effective
engraftment of transplanted cells should be explored.
Conclusion
In conclusion, our data showed that hFVIII-secreting ES cells
were capable of engraftment at the periportal area in the
liver and synthesizing hFVIII. Although development of a
safer induction method for liver regeneration is required,
our results showed the potential for developing an effective
cell transplantation therapeutic model for treating hemo-
philia A.
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